Mersana Therapeutics, Inc. (MRSN) News

Mersana Therapeutics, Inc. (MRSN): $5.00

0.09 (+1.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MRSN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Filter MRSN News Items

MRSN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

MRSN News Highlights

  • MRSN's 30 day story count now stands at 10.
  • Over the past 21 days, the trend for MRSN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • DCFC, DRUG and LYFT are the most mentioned tickers in articles about MRSN.

Latest MRSN News From Around the Web

Below are the latest news stories about Mersana Therapeutics Inc that investors may wish to consider to help them evaluate MRSN as an investment opportunity.

Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?

Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 24, 2022

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2021 Financial Results and Business Updates

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Monday, February 28, 2022 at 8:00 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2021 and provide business updates. T

Yahoo | February 22, 2022

Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 18, 2022

Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company’s management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET. A live webcast of the prese

Yahoo | February 10, 2022

DCFCW, MRSN and GRTS among after hour movers

Gainers:Enphase Energy (NASDAQ:ENPH) +16%. Tritium DCFC  (NASDAQ:DCFCW) +12%. Leafly Holdings (NASDAQ:LFLY) +11%. Tritium DCFC Limited (NASDAQ:DCFC) +9%. Mersana Therapeutics (NASDAQ:MRSN) +8%. Losers: Varex Imaging  (NASDAQ:VREX) -14%. QuinStreet (NASDAQ:QNST) -10%. Ichor Holdings (NASDAQ:ICHR) -6%. Lyft (NASDAQ:LYFT) -6%. Gritstone  (NASDAQ:GRTS) -5%....

Seeking Alpha | February 8, 2022

H.C. Wainwright Thinks Mersana Therapeutics’ Stock is Going to Recover

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report), with a price target of $28.00. The company's shares closed last Thursday at $4.29, close to its 52-week low of $4.11. According to TipRanks.com, White has 0 stars on 0-5 stars ranking scale with an average return of -3.2% and a 30.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mersana Therapeutics with a $22.60 average price target, implying a 413.

Christine Brown on TipRanks | February 4, 2022

Johnson & Johnson’s Jannsen unit in pact with Mersana for antibody-drug conjugates

Mersana Therapeutics (NASDAQ:MRSN) is trading ~7% higher in the pre-market after announcing a research collaboration and license agreement with Janssen Biotech of Johnson & Johnson (NYSE:JNJ) to develop antibody-drug conjugates for three targets. Per the terms, Janssen will deliver antibodies for the targets, and Mersana will leverage its Dolasynthen platform to develop...

Seeking Alpha | February 3, 2022

Janssen Inks Over $1B Pact For Mersana's ADC Technology In Three targets

Mersana Therapeutics Inc (NASDAQ: MRSN) has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), to discover antibody-drug conjugates (ADCs) for three targets. Janssen unit is doling out $40 million upfront and more than $1 billion in potential milestone payments for ADCs spanning three targets. The pair will work together to research target candidates during preclinical development. J&J's biotech unit will provide proprietar

Yahoo | February 3, 2022

Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates

Collaboration focused on discovering novel ADCs for three targets by leveraging Mersana’s ADC expertise and the Dolasynthen platform with Janssen’s proprietary antibodiesMersana receives $40 million upfront payment and potentially more than $1 billion in total milestones, plus mid-single-digit to low double-digit percentage royalties on net sales CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on dis

Yahoo | February 3, 2022

Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones

UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022 UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in platinum-sensitive ovarian cancer, expected to initiate in Q2 2022 Interim data from UPGRADE dose escalation umbrella trial of UpRi in combination with platinum planned for 2H 2022 Phase 1 dose escalation studies for two first-in-class candidates, XMT-1660, a Dolasynthen B7-H4 targeted ADC and XMT-2056, an I

Yahoo | January 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4868 seconds.